FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
Ambionics Achieves Breakthrough Development of Unique Child Prosthetic With Stratasys 3D Printing
These closed-end funds were unstoppable in early 2015; plus, did the first IPO of 2015 usher in a new era for CEF shareholders?
Dan Plettner invests and receives income for securities research, including “buy-side” research. Dan licenses his own real time trading data to Covestor Ltd. (“Covestor”), frequently including positions discussed in his Morningstar Contributions. Covestor is a Registered Investment Advisor that ...